Coherus director granted RSUs and stock options
Coherus Oncology director Charles W. Newton reported equity compensation grants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Coherus Oncology director Charles W. Newton reported equity compensation grants. He received 30,000 shares of Common Stock in the form of restricted stock units, with one share delivered for each unit upon vesting. The RSUs vest 100% on the one year anniversary of June 3, 2026, contingent on his continued service.
He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable in full on June 3, 2027, also subject to his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 options directly.
Insider Trade Summary
Grant/Award: 90,000 shares
Grant/Award
2 txns
Insider
Newton Charles W.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 30,000 shares (Direct)
Footnotes (2)
- F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- F2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Key Figures
RSU grant: 30,000 shares
Option grant: 60,000 options
Option exercise price: $1.45 per share
+5 more
8 metrics
RSU grant
30,000 shares
Restricted stock units tied to Common Stock
Option grant
60,000 options
Stock Option (Right to Buy) on Common Stock
Option exercise price
$1.45 per share
Conversion or exercise price for 60,000 options
Option expiration
June 5, 2036
Expiration date of stock options
RSU vesting date
One year anniversary of June 3, 2026
RSUs vest 100% on this date with continued service
Option vesting date
June 3, 2027
Options vest and become exercisable in full
Shares held after grant
30,000 shares
Common Stock held directly following RSU award
Options held after grant
60,000 options
Stock options held directly following award
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), exercise price, vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock and an exercise price of 1.4500."
exercise price financial
"conversion_or_exercise_price of 1.4500 per share for the stock options."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to continued service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The stock options have an expiration_date of June 5, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Charles W. Newton acquire in the latest Coherus (CHRS) Form 4?
Charles W. Newton received equity compensation, not open-market trades. He was granted 30,000 restricted stock units tied to Common Stock and stock options for 60,000 shares, all held directly, reflecting a standard board-level compensation structure at Coherus Oncology.
What are the terms of the 30,000 RSUs reported for Coherus (CHRS)?
The 30,000 RSUs entitle Newton to one share of Coherus Common Stock per unit upon vesting. According to the disclosure, 100% of these RSUs vest on the one year anniversary of June 3, 2026, conditioned on his continued service with the company.
What stock options did Charles W. Newton receive from Coherus (CHRS)?
Newton received stock options covering 60,000 shares of Coherus Common Stock at an exercise price of $1.45 per share. These options vest and become fully exercisable on June 3, 2027, and carry an expiration date of June 5, 2036, subject to continued service.
Are the Coherus (CHRS) RSU and option grants tied to service conditions?
Yes, both awards are service-based. The RSUs vest in full on the one year anniversary of June 3, 2026, and the options vest on June 3, 2027. In each case, vesting requires Newton’s continued service relationship with Coherus Oncology through the respective vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
